| Name | Conduritol B epoxide |
| Description | Conduritol B epoxide is an irreversible inhibitor of β-glucosidase (GCase). |
| Kinase Assay | Cells are homogenized in 1% sodium taurocholate/1% Triton X-100. GCase activity is determined fluorometrically using 4MU-Glucose as the substrate in 0.25% sodium taurocholate, 0.25% Triton X-100 and 0.1M citric-phosphate buffer (pH 5.6). Brain tissues are homogenized in 1X PBS and incubated in 5 μM brain phosphatidylserine and 0.1M citric-phosphate buffer (pH 5.6) for GCase activity assay using 4MU-Glucose as substrate. Protein concentrations are determined by BCA assay using BSA as standard [1]. |
| Animal Research | Gba1 point mutated 4L, 9H and 9V mice or WT mice are intraperitoneally injected with 100 mg/kg/day of Conduritol B epoxide. In short-term experiments, daily injections are initiated at postnatal day 5 and continued for 6 daily doses. The mice are sacrificed on day 12 or 2 months after the last injection. In long-term experiments, 4L mice are injected daily beginning at postnatal day 15 for 24 or 36 daily doses and sacrificed the day after the last injection. Mice are perfused with PBS and organs are harvested for enzyme activity, lipid, and histological analyses [2]. |
| In vitro | Treating N2a and Conduritol B epoxide-N2a cells with G6 reduced GC to 7% and 26% of untreated levels, respectively. G6-treated Conduritol B epoxide-N2a also exhibited significantly decreased GS. Conduritol B epoxide-N2a cells demonstrated higher baseline calcium levels than N2a cells without caffeine and showed a significant increase in cytosolic calcium levels compared to N2a cells. Additionally, Conduritol B epoxide-N2a cells exhibited a significant reduction in OCR, with approximately 50% reductions in ATP production rate, basal respiration, and maximal respiration compared to N2a cells. In dantrolene-treated Conduritol B epoxide-N2a cells, Ryr3 levels increased to 76% of the WT level [1]. |
| In vivo | Treatment with Conduritol B epoxide (100 mg/kg/day, i.p.) administered to 4L, 9H, 9V, and WT mice from postnatal days 5 to 11 does not result in the formation of α-synuclein aggregates. However, prolonged daily administration of this compound to 4L mice (at the same dosage starting from postnatal day 15 for either 24 or 36 doses) causes hind limb paralysis and leads to minimal α-synuclein accumulation in specific areas of the brain, including the olfactory bulb, brainstem, and periventricular region near the dorsal third ventricle (D3V) [2]. |
| Storage | Shipping with blue ice/Shipping at ambient temperature. |
| Solubility Information | 10% DMSO+40% PEG300+5% Tween 80+45% Saline : 4 mg/mL (24.67 mM), Sonication is recommended.
DMSO : 122.5 mg/mL (755.52 mM), Sonication is recommended.
H2O : ≥20 mg/mL (123.35 mM), Sonication is recommended.
|
| Keywords | α-glucosidase | Inhibitor | inhibit | Glucosidase | Conduritol B epoxide |
| Inhibitors Related | Cedryl acetate | X-GAL | Hexylresorcinol | Gcase activator 2 | Fucoidan | Miglitol | Ambroxol hydrochloride | D-(-)-Quinic acid | (E)-3-(4-Methoxyphenyl)acrylic acid | Naringinase | Acarbose | 3-Butylidenephthalide |
| Related Compound Libraries | Glycometabolism Compound Library | Bioactive Compound Library | Post-Translational Modification Compound Library | Inhibitor Library | NO PAINS Compound Library | Metabolism Compound Library | Bioactive Compounds Library Max | Covalent Inhibitor Library |
United States
